Translational Complementary Medicine (Gründemann)Head of Research Unit Prof. Dr.Carsten GründemannOverviewMembersPublicationsProjects & CollaborationsProjects & Collaborations OverviewMembersPublicationsProjects & Collaborations Projects & Collaborations 2 foundShow per page10 10 20 50 Viola tricolor as phytomedicine for the treatment of ulcerative colitis Research Project | 1 Project MembersInflammatory bowel disease is a chronic recurring disease of the gastrointestinal tract and can be manifested as ulcerative colitis. In Germany, Austria and Switzerland about 400,000 patients suffer from ulcerative colitis. Hereby, Europe has the highest reported prevalence worldwide with 505 per 100,000 people being affected Symptoms include diarrhea, abdominal cramps, and rectal bleeding. Considering current guidelines, anti-inflammatory and immunosuppressive drugs or biologics are used for treatment. Due to common adverse effects and lack of efficacy of standard therapies, a widespread discovery effort has been launched to identify new drugs from natural sources. Our scientific project aims to evaluate the use of herbal extracts of Viola tricolor as treatment of chronic inflammatory bowel diseases, especially ulcerative colitis. We have teamed up to perform cell-based signaling, mechanism-of-action and toxicity studies with tea infusions (Ph. Eur.) and experimental herbal violet extracts. Further, we aim to extract, isolate and chemically characterize novel immunomodulatory molecules from these preparations. Development of standardized extract preparation, based on the bioactive compounds of V. tricolor, will be employed. Furthermore, safety and efficacy of optimized herbal violet preparation will be assessed and documented following state-of-the-art Case Reporting guidelines, in a cohort of patients suffering from ulcerative colitis. Herbal safety in the pregnancy - Treatment options for nonpsychotic mental diseases Research Project | 5 Project MembersPregnancy is a critical period for medical care, well-being of both the woman and the embryo/foetus are to be considered. This is particularly relevant in the management of nonpsychotic mental disorders (NMD), since treatment with CNS-active drugs, but also untreated NMD may have negative effects. Some herbal preparations (phytopharmaceuticals) possess sedative, anxiolytic, or antidepressant properties. Since these preparations are often perceived as safe, their consumption during pregnancy might be high even though only a few studies have been conducted. Assessment of safety issues with phytopharmaceuticals is highly challenging. The active ingredients are multi-component mixtures of compounds, many of which undergo metabolisation by the intestinal microbiota upon oral administration, and metabolisation in the liver once reaching systemic blood circulation. Moreover, some of these compounds might be toxic and reach the embryo/foetus via the placenta. The project strives for characterising the safety of commonly used herbal medications for the treatment of NMD during pregnancy. Well-known herbal medications for these diseases are valerian, hops, golden poppy, lavender, and St. John's wort. Major aims of the project are: (1) characterisation of the use of herbal preparations during pregnancy, (2) analyses of their metabolisation by the intestinal flora and in the liver; (3) assessment of cytotoxicity and genotoxicity in vitro of these extracts and of critical compounds in extracts before and after metabolisation; (4) characterisation of intestinal absorption of the various compounds; (5) prediction of their hormone-disrupting effects and possible drug interactions; (6) assessment of effects on the function of immunocompetent cells and; (7) of placenta cell cultures; (8) investigation of their permeation across the placenta barrier. Whether the herbal preparations are commonly being used during pregnancy will be addressed with a survey in aim 1 (Zurich/A.P. Simões-Wüst, in collaboration with M. Puhan). To accomplish aim 2, the chemical composition of herbal preparations will be characterised before and after being metabolised by intestinal flora and liver microsomes (Basel/M. Hamburger, O. Potterat, in collaboration with C. Lacroix). Extracts and compounds (unmetabolised and metabolised) will be then submitted to cytotoxicity and genotoxicity assessment, in comparison with two synthetic CNS-active drugs that are frequently given during pregnancy, namely diazepam and citalopram. Cytotoxicity and genotoxicity will be tested in sensitive immunocompetent cells and in a placenta cell line (Freiburg/C. Gründemann). Hormone disruptive effects and possible drug interactions will be assessed in silico (Basel/M. Hamburger, O. Potterat, in collaboration with M. Smieško). Further experiments should clarify the impact of the herbal preparations on functional properties of immunocompetent cells (Freiburg/C. Gründemann), and of placenta cells (gene expression, Zurich/A.P. Simões-Wüst). At the same time, permeation across the placenta barrier will be assessed in a transwell model, and effects on functional properties in a placenta perfusion system (Zurich/A.P. Simões-Wüst, analytical support in Basel/M. Hamburger, O. Potterat). Knowing whether herbal preparations can be considered safe for use during pregnancy will provide a rational basis for decisions on the treatment of NMD during pregnancy. Taking into account the intestinal and hepatic metabolism is an entirely novel approach in the risk assessment of phytopharmaceuticals. The general approach, and the methodology developed in the project will be generically applicable to pharmacological and safety studies with phytomedicines. 1 1 OverviewMembersPublicationsProjects & Collaborations
Projects & Collaborations 2 foundShow per page10 10 20 50 Viola tricolor as phytomedicine for the treatment of ulcerative colitis Research Project | 1 Project MembersInflammatory bowel disease is a chronic recurring disease of the gastrointestinal tract and can be manifested as ulcerative colitis. In Germany, Austria and Switzerland about 400,000 patients suffer from ulcerative colitis. Hereby, Europe has the highest reported prevalence worldwide with 505 per 100,000 people being affected Symptoms include diarrhea, abdominal cramps, and rectal bleeding. Considering current guidelines, anti-inflammatory and immunosuppressive drugs or biologics are used for treatment. Due to common adverse effects and lack of efficacy of standard therapies, a widespread discovery effort has been launched to identify new drugs from natural sources. Our scientific project aims to evaluate the use of herbal extracts of Viola tricolor as treatment of chronic inflammatory bowel diseases, especially ulcerative colitis. We have teamed up to perform cell-based signaling, mechanism-of-action and toxicity studies with tea infusions (Ph. Eur.) and experimental herbal violet extracts. Further, we aim to extract, isolate and chemically characterize novel immunomodulatory molecules from these preparations. Development of standardized extract preparation, based on the bioactive compounds of V. tricolor, will be employed. Furthermore, safety and efficacy of optimized herbal violet preparation will be assessed and documented following state-of-the-art Case Reporting guidelines, in a cohort of patients suffering from ulcerative colitis. Herbal safety in the pregnancy - Treatment options for nonpsychotic mental diseases Research Project | 5 Project MembersPregnancy is a critical period for medical care, well-being of both the woman and the embryo/foetus are to be considered. This is particularly relevant in the management of nonpsychotic mental disorders (NMD), since treatment with CNS-active drugs, but also untreated NMD may have negative effects. Some herbal preparations (phytopharmaceuticals) possess sedative, anxiolytic, or antidepressant properties. Since these preparations are often perceived as safe, their consumption during pregnancy might be high even though only a few studies have been conducted. Assessment of safety issues with phytopharmaceuticals is highly challenging. The active ingredients are multi-component mixtures of compounds, many of which undergo metabolisation by the intestinal microbiota upon oral administration, and metabolisation in the liver once reaching systemic blood circulation. Moreover, some of these compounds might be toxic and reach the embryo/foetus via the placenta. The project strives for characterising the safety of commonly used herbal medications for the treatment of NMD during pregnancy. Well-known herbal medications for these diseases are valerian, hops, golden poppy, lavender, and St. John's wort. Major aims of the project are: (1) characterisation of the use of herbal preparations during pregnancy, (2) analyses of their metabolisation by the intestinal flora and in the liver; (3) assessment of cytotoxicity and genotoxicity in vitro of these extracts and of critical compounds in extracts before and after metabolisation; (4) characterisation of intestinal absorption of the various compounds; (5) prediction of their hormone-disrupting effects and possible drug interactions; (6) assessment of effects on the function of immunocompetent cells and; (7) of placenta cell cultures; (8) investigation of their permeation across the placenta barrier. Whether the herbal preparations are commonly being used during pregnancy will be addressed with a survey in aim 1 (Zurich/A.P. Simões-Wüst, in collaboration with M. Puhan). To accomplish aim 2, the chemical composition of herbal preparations will be characterised before and after being metabolised by intestinal flora and liver microsomes (Basel/M. Hamburger, O. Potterat, in collaboration with C. Lacroix). Extracts and compounds (unmetabolised and metabolised) will be then submitted to cytotoxicity and genotoxicity assessment, in comparison with two synthetic CNS-active drugs that are frequently given during pregnancy, namely diazepam and citalopram. Cytotoxicity and genotoxicity will be tested in sensitive immunocompetent cells and in a placenta cell line (Freiburg/C. Gründemann). Hormone disruptive effects and possible drug interactions will be assessed in silico (Basel/M. Hamburger, O. Potterat, in collaboration with M. Smieško). Further experiments should clarify the impact of the herbal preparations on functional properties of immunocompetent cells (Freiburg/C. Gründemann), and of placenta cells (gene expression, Zurich/A.P. Simões-Wüst). At the same time, permeation across the placenta barrier will be assessed in a transwell model, and effects on functional properties in a placenta perfusion system (Zurich/A.P. Simões-Wüst, analytical support in Basel/M. Hamburger, O. Potterat). Knowing whether herbal preparations can be considered safe for use during pregnancy will provide a rational basis for decisions on the treatment of NMD during pregnancy. Taking into account the intestinal and hepatic metabolism is an entirely novel approach in the risk assessment of phytopharmaceuticals. The general approach, and the methodology developed in the project will be generically applicable to pharmacological and safety studies with phytomedicines. 1 1
Viola tricolor as phytomedicine for the treatment of ulcerative colitis Research Project | 1 Project MembersInflammatory bowel disease is a chronic recurring disease of the gastrointestinal tract and can be manifested as ulcerative colitis. In Germany, Austria and Switzerland about 400,000 patients suffer from ulcerative colitis. Hereby, Europe has the highest reported prevalence worldwide with 505 per 100,000 people being affected Symptoms include diarrhea, abdominal cramps, and rectal bleeding. Considering current guidelines, anti-inflammatory and immunosuppressive drugs or biologics are used for treatment. Due to common adverse effects and lack of efficacy of standard therapies, a widespread discovery effort has been launched to identify new drugs from natural sources. Our scientific project aims to evaluate the use of herbal extracts of Viola tricolor as treatment of chronic inflammatory bowel diseases, especially ulcerative colitis. We have teamed up to perform cell-based signaling, mechanism-of-action and toxicity studies with tea infusions (Ph. Eur.) and experimental herbal violet extracts. Further, we aim to extract, isolate and chemically characterize novel immunomodulatory molecules from these preparations. Development of standardized extract preparation, based on the bioactive compounds of V. tricolor, will be employed. Furthermore, safety and efficacy of optimized herbal violet preparation will be assessed and documented following state-of-the-art Case Reporting guidelines, in a cohort of patients suffering from ulcerative colitis.
Herbal safety in the pregnancy - Treatment options for nonpsychotic mental diseases Research Project | 5 Project MembersPregnancy is a critical period for medical care, well-being of both the woman and the embryo/foetus are to be considered. This is particularly relevant in the management of nonpsychotic mental disorders (NMD), since treatment with CNS-active drugs, but also untreated NMD may have negative effects. Some herbal preparations (phytopharmaceuticals) possess sedative, anxiolytic, or antidepressant properties. Since these preparations are often perceived as safe, their consumption during pregnancy might be high even though only a few studies have been conducted. Assessment of safety issues with phytopharmaceuticals is highly challenging. The active ingredients are multi-component mixtures of compounds, many of which undergo metabolisation by the intestinal microbiota upon oral administration, and metabolisation in the liver once reaching systemic blood circulation. Moreover, some of these compounds might be toxic and reach the embryo/foetus via the placenta. The project strives for characterising the safety of commonly used herbal medications for the treatment of NMD during pregnancy. Well-known herbal medications for these diseases are valerian, hops, golden poppy, lavender, and St. John's wort. Major aims of the project are: (1) characterisation of the use of herbal preparations during pregnancy, (2) analyses of their metabolisation by the intestinal flora and in the liver; (3) assessment of cytotoxicity and genotoxicity in vitro of these extracts and of critical compounds in extracts before and after metabolisation; (4) characterisation of intestinal absorption of the various compounds; (5) prediction of their hormone-disrupting effects and possible drug interactions; (6) assessment of effects on the function of immunocompetent cells and; (7) of placenta cell cultures; (8) investigation of their permeation across the placenta barrier. Whether the herbal preparations are commonly being used during pregnancy will be addressed with a survey in aim 1 (Zurich/A.P. Simões-Wüst, in collaboration with M. Puhan). To accomplish aim 2, the chemical composition of herbal preparations will be characterised before and after being metabolised by intestinal flora and liver microsomes (Basel/M. Hamburger, O. Potterat, in collaboration with C. Lacroix). Extracts and compounds (unmetabolised and metabolised) will be then submitted to cytotoxicity and genotoxicity assessment, in comparison with two synthetic CNS-active drugs that are frequently given during pregnancy, namely diazepam and citalopram. Cytotoxicity and genotoxicity will be tested in sensitive immunocompetent cells and in a placenta cell line (Freiburg/C. Gründemann). Hormone disruptive effects and possible drug interactions will be assessed in silico (Basel/M. Hamburger, O. Potterat, in collaboration with M. Smieško). Further experiments should clarify the impact of the herbal preparations on functional properties of immunocompetent cells (Freiburg/C. Gründemann), and of placenta cells (gene expression, Zurich/A.P. Simões-Wüst). At the same time, permeation across the placenta barrier will be assessed in a transwell model, and effects on functional properties in a placenta perfusion system (Zurich/A.P. Simões-Wüst, analytical support in Basel/M. Hamburger, O. Potterat). Knowing whether herbal preparations can be considered safe for use during pregnancy will provide a rational basis for decisions on the treatment of NMD during pregnancy. Taking into account the intestinal and hepatic metabolism is an entirely novel approach in the risk assessment of phytopharmaceuticals. The general approach, and the methodology developed in the project will be generically applicable to pharmacological and safety studies with phytomedicines.
